Literature DB >> 17698656

Virus distribution of the attenuated MVA and NYVAC poxvirus strains in mice.

Carmen Elena Gómez1, José Luis Nájera, Elena Domingo-Gil, Laura Ochoa-Callejero, Gloria González-Aseguinolaza, Mariano Esteban.   

Abstract

Recombinant vaccinia viruses based on the attenuated NYVAC and MVA strains are promising vaccine candidates against a broad spectrum of diseases. Whilst these vectors are safe and immunogenic in animals and humans, little is known about their comparative behaviour in vivo. In this investigation, a head-to-head analysis was carried out of virus dissemination in mice inoculated by the mucosal or systemic route with replication-competent (WRluc) and attenuated recombinant (MVAluc and NYVACluc) viruses expressing the luciferase gene. Bioluminescence imaging showed that, in contrast to WRluc, the attenuated recombinants expressed the reporter gene transiently, with MVAluc expression limited to the first 24 h and NYVACluc giving a longer signal, up to 72 h post-infection, for most of the routes assayed. Moreover, luciferase levels in MVAluc-infected tissues peaked earlier than those in tissues infected by NYVACluc. These findings may be of immunological relevance when these vectors are used as recombinant vaccines.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17698656     DOI: 10.1099/vir.0.83018-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  22 in total

1.  Selective induction of host genes by MVA-B, a candidate vaccine against HIV/AIDS.

Authors:  Susana Guerra; José Manuel González; Núria Climent; Hugh Reyburn; Luis A López-Fernández; José L Nájera; Carmen E Gómez; Felipe García; José M Gatell; Teresa Gallart; Mariano Esteban
Journal:  J Virol       Date:  2010-06-09       Impact factor: 5.103

2.  Role of cell signaling in poxvirus-mediated foreign gene expression in mammalian cells.

Authors:  Ningjie Hu; Richard Yu; Cecilia Shikuma; Bruce Shiramizu; Mario A Ostrwoski; Qigui Yu
Journal:  Vaccine       Date:  2009-03-10       Impact factor: 3.641

3.  Original encounter with antigen determines antigen-presenting cell imprinting of the quality of the immune response in mice.

Authors:  Valérie Abadie; Olivia Bonduelle; Darragh Duffy; Christophe Parizot; Bernard Verrier; Béhazine Combadière
Journal:  PLoS One       Date:  2009-12-07       Impact factor: 3.240

4.  Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens.

Authors:  José Luis Nájera; Carmen Elena Gómez; Juan García-Arriaza; Carlos Oscar Sorzano; Mariano Esteban
Journal:  PLoS One       Date:  2010-06-30       Impact factor: 3.240

5.  Attenuated and replication-competent vaccinia virus strains M65 and M101 with distinct biology and immunogenicity as potential vaccine candidates against pathogens.

Authors:  Lucas Sánchez-Sampedro; Carmen Elena Gómez; Ernesto Mejías-Pérez; Eva Pérez-Jiménez; Juan Carlos Oliveros; Mariano Esteban
Journal:  J Virol       Date:  2013-04-17       Impact factor: 5.103

6.  Application of bioluminescence imaging to the prediction of lethality in vaccinia virus-infected mice.

Authors:  Marina Zaitseva; Senta M Kapnick; John Scott; Lisa R King; Jody Manischewitz; Lev Sirota; Shantha Kodihalli; Hana Golding
Journal:  J Virol       Date:  2009-08-05       Impact factor: 5.103

7.  Rapid expansion of CD8+ T cells in wild-type and type I interferon receptor-deficient mice correlates with protection after low-dose emergency immunization with modified vaccinia virus Ankara.

Authors:  Asisa Volz; Martin Langenmayer; Sylvia Jany; Ulrich Kalinke; Gerd Sutter
Journal:  J Virol       Date:  2014-07-09       Impact factor: 5.103

8.  Differential CD4+ versus CD8+ T-cell responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates.

Authors:  Petra Mooij; Sunita S Balla-Jhagjhoorsingh; Gerrit Koopman; Niels Beenhakker; Patricia van Haaften; Ilona Baak; Ivonne G Nieuwenhuis; Ivanela Kondova; Ralf Wagner; Hans Wolf; Carmen E Gómez; José L Nájera; Victoria Jiménez; Mariano Esteban; Jonathan L Heeney
Journal:  J Virol       Date:  2008-01-09       Impact factor: 5.103

9.  Organism-Level Analysis of Vaccination Reveals Networks of Protection across Tissues.

Authors:  Motohiko Kadoki; Ashwini Patil; Cornelius C Thaiss; Donald J Brooks; Surya Pandey; Deeksha Deep; David Alvarez; Ulrich H von Andrian; Amy J Wagers; Kenta Nakai; Tarjei S Mikkelsen; Magali Soumillon; Nicolas Chevrier
Journal:  Cell       Date:  2017-09-21       Impact factor: 66.850

10.  Evaluation of in vitro cross-reactivity to avian H5N1 and pandemic H1N1 2009 influenza following prime boost regimens of seasonal influenza vaccination in healthy human subjects: a randomised trial.

Authors:  Delia Bethell; David Saunders; Anan Jongkaewwattana; Jarin Kramyu; Arunee Thitithayanont; Suwimon Wiboon-ut; Kosol Yongvanitchit; Amporn Limsalakpetch; Utaiwan Kum-Arb; Nichapat Uthaimongkol; Jean Michel Garcia; Ans E Timmermans; Malik Peiris; Stephen Thomas; Anneke Engering; Richard G Jarman; Duangrat Mongkolsirichaikul; Carl Mason; Nuanpan Khemnu; Stuart D Tyner; Mark M Fukuda; Douglas S Walsh; Sathit Pichyangkul
Journal:  PLoS One       Date:  2013-03-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.